119-HR-6703 Journalist Public Summary
119 · HR 6703 Lower Health Care Premiums for All Americans Act
Plain‑English overview of H.R. 6703 (introduced December 15, 2025): expands association health plans and individual-coverage HRAs, clarifies stop‑loss rules, adds new pharmacy benefit manager transparency with penalties, and resumes Affordable Care Act cost‑sharing reduction funding (with abortion‑coverage limits).
Headline Summary
A broad health insurance bill aiming to lower premiums by expanding employer options, tightening oversight of pharmacy benefit managers (PBMs), and restarting certain ACA subsidies—with new rules for who can buy what and how plans are regulated.
What It Does
The bill, titled the “Lower Health Care Premiums for All Americans Act,” bundles several changes meant to expand coverage choices and reduce costs for workers, small businesses, and the self‑employed, while increasing transparency around prescription drug spending.
- Association Health Plans (AHPs): Lets groups of employers—across different industries—band together to offer a single group health plan if they meet governance and nondiscrimination rules. Self‑employed people can join if they truly run a business and meet work‑hour tests.
- Premium rules for AHPs: Allows a base community rate for the plan, then permits employer‑by‑employer adjustments based on risk; if the association is only self‑employed individuals, everyone pays the same rate.
- Stop‑loss insurance: Clarifies that stop‑loss purchased by self‑funded employer plans isn’t treated as “health insurance,” and preempts state laws that would block group plans from protecting against unusually high claims.
- HRAs tied to individual coverage: Codifies and broadens individual‑coverage HRA (called a “custom health option and individual care expense arrangement”), with nondiscrimination, substantiation, and notice requirements. Employees in these HRAs could pay individual‑market premiums pre‑tax via cafeteria plans. W‑2 reporting of HRA benefits is added. Effective for plan years beginning after December 31, 2025.
- PBM oversight and transparency: Starting roughly 30 months after enactment, PBMs must send semiannual reports to group plans with detailed drug pricing, rebates, fees, and affiliated‑pharmacy data; participants can request summaries. Civil penalties apply for noncompliance and false reporting.
- Restarts ACA cost‑sharing reduction (CSR) payments: Permanently appropriates funds for CSR payments beginning with plan years starting on or after January 1, 2027, but bars payments for plans that cover abortion beyond life‑of‑the‑mother, rape, or incest exceptions.
Who’s For It
Sponsor: Rep. Mariannette Miller‑Meeks of Iowa introduced H.R. 6703 on December 15, 2025. The bill was referred to the House Committees on Energy and Commerce; Education and the Workforce; and Ways and Means.
- Small businesses and trade associations seeking lower premiums and more purchasing power via AHPs.
- Employers that self‑fund benefits and use stop‑loss, which the bill shields from being regulated like full insurance.
- Benefits consultants and some insurers supportive of HRAs and pre‑tax payments for individual‑market coverage, arguing this widens choices for workers who don’t fit traditional group plans.
- Plan sponsors and employers pressing for PBM transparency to see true net drug costs and reduce spread pricing.
Who’s Against It
- Patient and consumer advocates who warn AHPs can segment healthier groups from ACA markets, potentially weakening protections or raising premiums for those left behind.
- State insurance regulators concerned that reclassifying stop‑loss and preempting certain state rules could limit state oversight of employer plans and shift risk to providers or patients.
- Some ACA supporters who fear pre‑tax cafeteria plan payments for exchange coverage could complicate marketplaces and risk‑pooling, and that HRA class‑based offerings could disadvantage certain workers.
- Reproductive‑rights groups objecting to CSR funding limits tied to abortion coverage, which could reduce plan options in some states.
- PBMs and affiliated pharmacies facing extensive data‑sharing and penalties, arguing compliance costs and disclosure of proprietary terms could be burdensome or anti‑competitive.
What’s Next
Status as of December 15, 2025: Introduced and referred to House committees (Energy and Commerce; Education and the Workforce; Ways and Means). Next steps typically include hearings, potential markups, and a House floor vote. If it passes the House, the bill would move to the Senate and, if approved there, to the President.
Discussion